Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate plus adalimumab to reduce immunogenicity in ankylosing spondylitis
2012-004939-23Phase 4Active
- Sponsor
- CHRU Tours
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methotrexate and adalimumab in ankylosing spondylitis (AS) (2 arms), sponsored by CHRU Tours. Primary endpoint: Presence of anti-adalimumab antibodies at 26 weeks. Started Oct 2021; status: active.
02
Drugs
methotrexateadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2012-004939-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004939-23.